Business
Twist Bioscience and Ginkgo Bioworks Revise Collaboration
SOUTH SAN FRANCISCO, Calif. & BOSTON, May 08, 2025--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that the companies have entered into an updated collaboration renegotiated from a prior contract signed in 2022.
About this update from Ginkgo Bioworks Holdings, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":240,"url":"https://media.zenfs.com/en/business-wire.com/9f6327d9de7ecc9e710bdb0d9e35797f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qfXZV7gy6j_E0lOSdyqLAw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/9f6327d9de7ecc9e710bdb0d9e35797f","width":480,"height":240}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1431,"height":388,"url":"https://media.zenfs.com/en/business-wire.com/50f25194a4d091dd19782302b0bf0115"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/g3TferJekp2rCWoMuJMxuQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/50f25194a4d091dd19782302b0bf0115","width":960,"height":260},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/kpy99y3sN.cenxUEbcaZRg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02NTA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/50f25194a4d091dd19782302b0bf0115","width":1200,"height":325}}},{"type":"text","content":"New terms provide Twist with key license to long DNA technology and assets","length":74,"tagName":"p","attribs":{}},{"type":"text","content":"Ginkgo to continue ordering from Twist with no purchase minimums","length":64,"tagName":"p","attribs":{}},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif. & BOSTON, May 08, 2025--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that the companies have entered into an updated collaboration renegotiated from a prior contract signed in 2022.","length":459,"tagName":"p"},{"type":"text","content":"Under the terms of the revised three-year $15 million agreement, Ginkgo will continue to be a valued customer of Twist and will prepay annually for orders of Twist’s high-quality DNA products, underscoring the enduring value and reliability of Twist’s synthesis capabilities. Ginkgo will receive preferential pricing for DNA products with no re...